James Abbruzzese, MD

Professor of Medicine
D. C. I. Distinguished Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., The University of Chicago, 1978

Publications

Turner, Megan C., Marcelo Cerullo, Mohamed Adam, Kevin N. Shah, Dan G. Blazer, James L. Abbruzzese, and Sabino Zani. “Adjuvant Chemotherapy Should Follow Pancreaticoduodenectomy for Pancreatic Adenocarcinoma, Despite Delays.” In Journal of the American College of Surgeons, 227:S169–S169. Ovid Technologies (Wolters Kluwer Health), 2018. https://doi.org/10.1016/j.jamcollsurg.2018.07.359.

Full Text

Moschos, S. J., Z. Eroglu, N. I. Khushalani, K. L. Kendra, G. Ansstas, G. K. In, P. Wang, et al. “NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).” In Ann Oncol, 29 Suppl 8:viii453, 2018. https://doi.org/10.1093/annonc/mdy289.024.

PMID
32137157
Full Text

Safe, Stephen, James Abbruzzese, Maen Abdelrahim, and Erik Hedrick. “Specificity Protein Transcription Factors and Cancer: Opportunities for Drug Development.” Cancer Prev Res (Phila) 11, no. 7 (July 2018): 371–82. https://doi.org/10.1158/1940-6207.CAPR-17-0407.

PMID
29545399
Full Text

Palta, Manisha, Brian G. Czito, Eileen Duffy, Mary Malicki, Donna Niedzwiecki, James L. Abbruzzese, Hope Elizabeth Uronis, Gerard C. Blobe, Dan G. Blazer, and Christopher Willett. “A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.” In Journal of Clinical Oncology, 36:4121–4121. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4121.

Full Text

Liu, Joyce F., William Thomas Barry, Robert Michael Wenham, Andrea Elisabeth Wahner Hendrickson, Deborah Kay Armstrong, Nancy Chan, David E. Cohn, et al. “A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).” In Journal of Clinical Oncology, 36:5519–5519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5519.

Full Text

Duan, Bensong, Jiangfeng Hu, Hongliang Liu, Yanru Wang, Hongyu Li, Shun Liu, Jichun Xie, et al. “Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk.” Int J Cancer 142, no. 7 (April 1, 2018): 1322–31. https://doi.org/10.1002/ijc.31171.

PMID
29168174
Full Text

Berlin, Jordan D., Yang Feng, Paul Catalano, James L. Abbruzzese, Philip A. Philip, Robert R. McWilliams, Andrew M. Lowy, Al B. Benson, and A William Blackstock. “An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).” Oncology 94, no. 1 (2018): 39–46. https://doi.org/10.1159/000480295.

PMID
29040974
Full Text

Andersen, Dana K., Murray Korc, Gloria M. Petersen, Guido Eibl, Donghui Li, Michael R. Rickels, Suresh T. Chari, and James L. Abbruzzese. “Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer.” Diabetes 66, no. 5 (May 2017): 1103–10. https://doi.org/10.2337/db16-1477.

PMID
28507210
Full Text

Pages